Glioblastoma (GBM), now classified as CNS WHO grade 4 adult-type diffuse glioma, is the most aggressive and common malignant brain tumor in adults. Despite advancements in surgery, radiation therapy (RT), and chemotherapy (notably temozolomide), prognosis remains poor—median survival is 15–17 months and <10% survive 5 years.
Historically, GBM classification relied solely on histology, but the 2021 WHO CNS classification incorporates molecular markers for more accurate diagnosis and prognosis. Key molecular features defining WHO grade 4 diffuse glioma include:
-
IDH-wildtype astrocytoma with:
-
EGFR amplification
-
Gain of chromosome 7/loss of chromosome 10
-
TERT promoter mutation
-
-
CDKN2A/B homozygous deletion in IDH-mutant gliomas
These markers can now reclassify some tumors previously labeled as grade 2 or 3 into grade 4, even without necrosis or vascular proliferation.
Importantly, only IDH-wildtype tumors are now classified as GBM, whereas IDH-mutant grade 4 tumors are termed astrocytoma, IDH-mutant, WHO grade 4.
This updated ASTRO guideline replaces the 2016 version, aligning with modern molecular classifications and addressing disparities in care to guide future research and equitable treatment.